Tumor-Infiltrating lymphocytes in breast cancer: Ready for prime time?

Journal of Clinical Oncology

Volumn 33, Issue 11, 2015, Pages 1298-1299

  Ocañã, Alberto ^a   Diez Gónzález, Laura ^a   Adrover, Encarna ^a   Fernández Aramburo, Antonio ^a   Pandiella, Atanasio ^b   Amir, Eitan ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b CSIC   (Spain)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; FEMALE; PATHOLOGY; TRIPLE NEGATIVE BREAST CANCER;

TUMOR MARKER;

FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84927138901     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.7286     Document Type: Letter

References (10)

1. Adams S, Gray RJ, Demaria S, et al: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959-2967, 2014
2. Demir L, Yigit S, Ellidokuz H, et al: Predictive and prognostic factors in locally advanced breast cancer: Effect of intratumoral FOXP3- Tregs. Clin Exp Metastasis 30:1047-1062, 2013
3. Lee S, Cho EY, Park YH, et al: Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol 52:73-81, 2013
4. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860-867, 2013
5. Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 25:1544-1550, 2014
6. Ma C, Zhang Q, Ye J, et al: Tumor-infiltrating - T lymphocytes predict clinical outcome in human breast cancer. J Immunol 189:5029-5036, 2012
7. Muenst S, Soysal SD, Gao F, et al: The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 139:667-676, 2013
8. Rathore AS, Kumar S, Konwar R, et al: Presence of CD3- tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. Indian J Cancer 50:239-244, 2013
9. Sun S, Fei X, Mao Y, et al: PD-1(-) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother 63:395-406, 2014
10. Salgado R, Denkert C, Demaria S, et al: Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs-working group. Ann Oncol [epub ahead of print on September 11, 2014]